In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finding The Exit: Forbion On Roche’s Acquisition Of Inflazome

Executive Summary

Two years after leading a $46m series B financing round in Inflazome, a four-year old Irish biotech developing oral NLRP3 inflammasome inhibitors, VC firm Forbion is celebrating Roche’s $446m acquisition of the company, which includes the potential for additional milestone payments. Forbion general partner Marco Boorsa, who joined Inflazome’s board of directors in November 2018, spoke with In Vivo about the VC firm’s investment strategy.

You may also be interested in...



Roche Bulks Up In NLRP3 With €380m Inflazome Buy

Having acquired Jecure Therapeutics and its preclinical portfolio of NLRP3 inhibitors just under two years ago, the Swiss giant has swooped in to buy Dublin-based Inflazome and expand its presence in a hot field of inflammatory research.

Bayer Hopeful Of Sweet Success With KaNDy Buy

Bayer is paying $425m upfront to acquire KaNDy Therapeutics, whose CEO tells Scrip that the German group was always the preferred partner due to its long-standing commitment to women’s health.

Managing The Expansion of Clinical Trial Data Sources

Increases in remote patient monitoring and decentralized clinical trials – accelerated by COVID-19 – have added complexity to data management systems. Traditional platforms and electronic data capture used by drug development sponsors are ineffectual tools for integrating new primary data sources, or managing remote patient monitoring, Raj Indupuri, CEO at eClinical Solutions told In Vivo. 

Topics

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel